618 Matching Annotations
  1. Aug 2022
    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

    1. Sadoff, J., Gars, M. L., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., Groot, A. M. de, Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Hoof, J. V., Douoguih, M., & Schuitemaker, H. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (p. 2021.08.25.21262569). https://doi.org/10.1101/2021.08.25.21262569

    1. Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S. K., Medigeshi, G., Singh, J., Shaman, H., Singh, C., & Rao, A. V. (2022). Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (p. 2022.03.08.22271822). medRxiv. https://doi.org/10.1101/2022.03.08.22271822

    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

    1. Collier, A. Y., Brown, C. M., Mcmahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J. L., Rowe, M., Sellers, D., Ahmad, K., Aguayo, R., Anioke, T., Gardner, S., Siamatu, M., Rivera, L. B., Hacker, M. R., Madoff, L. C., & Barouch, D. H. (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (p. 2021.10.18.21265113). https://doi.org/10.1101/2021.10.18.21265113

    1. John Bye [@_johnbye]. (2021, October 6). The new covid sceptic All Party Parliamentary Group on Pandemic Response and Recovery is backed by Gupta and Heneghan’s Collateral Global to the tune of over £30,000. £5,000 in financial benefits plus £25,501—£27,000 benefits in kind (CG is acting as their secretariat). Https://t.co/qll20Sg9aA [Tweet]. Twitter. https://twitter.com/_johnbye/status/1445867760819396608

  2. Apr 2022
    1. Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., Manne, S., Chen, Z., Huang, Y. J., Reilly, J. P., Weisman, A. R., Ittner, C. A. G., Kuthuru, O., Dougherty, J., Nzingha, K., … Wherry, E. J. (2020). Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 369(6508), eabc8511. https://doi.org/10.1126/science.abc8511

    1. ReconfigBehSci. (2021, November 2). @jeremy_hume personally, I’d consider it a natural, considerate, and moral response to avoid contact with others when carrying an infection that can be dangerous to others. So what seems dystopian to me, is not doing so, and not creating the social/financial conditions that allow it. [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1455499076850655235

  3. Mar 2022
    1. ReconfigBehSci on Twitter: ‘@STWorg @ProfColinDavis @rpancost @chrisdc77 @syrpis this is the most in depth treatment of the impact of equalities law on pandemic policy that I’ve been able to find- it would seem to underscore that there is a legal need for impact assessments that ask (some) of these questions https://t.co/auiApVC0TW’ / Twitter. (n.d.). Retrieved 22 March 2022, from https://twitter.com/SciBeh/status/1485927221449613314

  4. Feb 2022
    1. Dr. Deepti Gurdasani. (2022, February 21). Did anyone hear any mention of long COVID, an illness affecting 1.3 million people, of whom 500,000 have had this for more than a year during the briefing? Are we just going to pretend it doesn’t exist? [Tweet]. @dgurdasani1. https://twitter.com/dgurdasani1/status/1495839416262311938

    1. Timothy Caulfield. (2022, January 31). How Do You Respond When an #AntiVaxxer Dies of Covid? Https://nytimes.com/2022/01/30/opinion/culture/covid-death-mental-health.html?smid=tw-share by @JamesMartinSJ “Indulged in regularly, #schadenfreude ends up warping the soul.” “Don’t find another person’s misery the subject of mirth, glee or satisfaction.” Good reminder. One I needed. [Tweet]. @CaulfieldTim. https://twitter.com/CaulfieldTim/status/1488183630056755205

  5. Jan 2022
    1. Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J., Wolf, C., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., Briggs-Hagen, M., Saydah, S., Midgley, C. M., Pringle, K., Chu, H., Bloom, J. D., & Englund, J. A. (2022). Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time (p. 2022.01.14.22269235). medRxiv. https://doi.org/10.1101/2022.01.14.22269235

    1. Dr. Thrasher wrote a book! (2022, January 8). My cousin wanted to get tested. She waited in an auto testing line for 6.5 hours, and stayed in it bc she was traveling to bury her Daddy. How many people give up in such long lines? How many cases upwards of a million are we losing bc Biden et all failed on home tests? Https://t.co/Q7WVy5qD4v [Tweet]. @thrasherxy. https://twitter.com/thrasherxy/status/1479826389142491146

    1. ReconfigBehSci. (2022, January 9). Just a thought on this and the general vaccine mandate debate. As a behavioural scientist currently stuck in Germany where this is a live debate, it strikes me that the thoughts below address only part of the population: Those not currently vaccinated. But what about ... 1/2 [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1480213148032450565

    1. ReconfigBehSci. (2022, January 9). There are many things I would not have believed about the pandemic pre 2020, but top of them is the fact that Western nations would completely ignore 24 months worth of actually implemented policies that were vastly more successful [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1480162136240398339

    1. Home

      Zuo, F., Abolhassani, H., Du, L., Piralla, A., Bertoglio, F., Campos-Mata, L. de, Wan, H., Schubert, M., Wang, Y., Sun, R., Cassaniti, I., Vlachiotis, S., Kumagai-Braesch, M., Andréll, J., Zhang, Z., Xue, Y., Wenzel, E. V., Calzolai, L., Varani, L., … Pan-Hammarström, Q. (2022). Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant (p. 2022.01.04.22268755). https://doi.org/10.1101/2022.01.04.22268755

    1. Will Stancil. (2022, January 11). The US reported 1.4 million COVID cases yesterday and hospitalizations are the highest ever. We’re sailing into this hurricane with virtually no effort to change course because fancy people believe they have a god-given right to their normal lives, no matter how bad things get. [Tweet]. @whstancil. https://twitter.com/whstancil/status/1480914594243792904

  6. Dec 2021
    1. Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., Anton, L., Weber, L. M., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Hörber, S., Peter, A., Meisner, C., … Walz, J. S. (2021). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04232-5

    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  7. Nov 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0